FDA OK's Amgen's Neupogen for radiation exposure
This article was originally published in Scrip
Executive Summary
The FDA has OK'd Amgen's Neupogen (filgrastim) as the first medical countermeasure for adults and pediatric patients acutely exposed to myelosuppressive doses of radiation, causing hematopoietic syndrome of acute radiation syndrome (H-ARS).